The field of genomics has surpassed expectations over the past three decades due to massive changes in technology that allowed researchers to interrogate larger pieces of the human genome. The NGS technology has potential to become ultimate genotyping platform for human identification. The capability of NGS led its application as forensic markers such as short tandem repeats (STR), mitochondrial and Y-chromosome haplotypes. The rapidly decreasing cost of sequencing per base in conjunction with the introduction of cost-effective benchtop laboratory sequencers has sparked growing demand in the field of personalized medicine for the incorporation of discrete NGS data within the clinical arena. “Meticulous Research” in its latest publication states that, the “global market for NGS services is expected to grow at a CAGR of 20.1% from 2018 to 2023 to reach $2,921.4 million by 2023.”
This growth is primarily driven by plummeting cost of sequencing, need of skilled professionals for efficient NGS sample preparation and analysis, technological advancements in NGS services, increase in genome mapping programs, and high cost of sequencing infrastructures.
Technological advancement in biotechnology has changed the dynamics of overall NGS market in recent times. The Human Genome Project (HGP), required vast amounts of time and resources for completion of the project. Prior to completion, it was clear that faster, higher throughput, and cheaper technologies were required to sequence various organism’s genomes. For this reason, in 2004, the National Human Genome Research Institute (NHGRI) initiated a funding program with the goal of reducing the cost of human genome sequencing to USD 1,000 in next ten years.
The enormous numbers of reads generated by NGS enabled the sequencing of entire genomes at an unprecedented speed. However, a drawback of NGS technologies was the relatively short reads of a sequence that made it difficult to understand the NGS data. The technological advancement in NGS technology was observed in terms of the development of various platforms in the past decade. The first NGS technology to be released in 2005 was the pyrosequencing method by 454 Life Sciences (now Roche). The 454 Genome Sequencer generated about 200,000 reads (~20 MB) of 110 base pairs (bp). In 2007, Illumina, Inc. acquired Solexa sequencing platform, which supports to perform genome-scale technology for genotyping, gene expression, and sequencing, the three cornerstones of modern genetic analysis.
The third technology to be released was Sequencing by Oligo Ligation Detection (SOLiD) by Applied Biosystems (now Life Technologies) in 2007. Further, in 2010, Ion Torrent (now Life Technologies) released the Personal Genome Machine (PGM).
Browse in-depth Report on https://www.meticulousresearch.com/product/next-generation-sequencing-ngs-services-market/
Through the upgradation in sequencing machines and improvements in base calling software and in sequencing chemistries, Illumina technology can now generate reads of several hundreds of bp long. Furthermore, the particularly impressive increase in throughput has been achieved by Illumina, which currently offers the highest throughput per run and the lowest per base cost.
In January 2014, Illumina released the HiSeq X Ten, a set of ten HiSeq X sequencing machines, with the staggering capacity to generate up to 1.8 Tb of sequence per run. Furthermore, the technological advancements in NGS have led to its widespread use and have raised a growing interest for its usage in clinical applications. For instance, improvements and new developments in NGS technologies can produce extensive coverage, representing accurately all significant genomic regions and thus limiting artifacts for analysis of genetic diseases, providing a realistic clinical PGS/PGD scenario.
Thus, the explosive development of genomics technologies including microarrays and advances in DNA sequencing, resulting in the advent of NGS provides opportunity to implement comprehensive chromosome screening approaches, consequently driving the growth of NGS services market.
The report provides meticulous analysis of NGS services market on the basis of Service Type (Targeted sequencing, RNA Sequencing, Exome Sequencing, De Novo Sequencing, ChIP-Sequencing, Whole Genome Sequencing, Methyl Sequencing, and Other Services),Technology [Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing (IOS), Single Molecule Real Time Sequencing (SMRT), Nanopore Sequencing, and True Single Molecule Sequencing (tSMS)], Application (Diagnostics, Drug Discovery, Biomarker Discovery, Agriculture & Animal Research, and Other Applications), End User (Academic& Research Institutes, Pharmaceuticals & Biotechnology Industry, Hospitals & Clinics and Other End Users), and Geography.
The key players analyzed in the NGS Services Market are Illumina, Inc.(U.S.), Qiagen N.V.(The Netherlands), PerkinElmer, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), GATC Biotech AG (Germany), Macrogen, Inc. (South Korea), Genotypic Technology Pvt. Ltd. (India), GENEWIZ, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), SciGenom Labs Pvt. Ltd. (India), MedGenome (India), DNA Link, Inc. (South Korea), Otogenetics Corporation (U.S.), Novogene Corporation (China), LGC Limited (U.K.), CD Genomics (U.S.), and SeqLL, LLC (U.S.).
Download free sample report and detailed Table of Content here: https://www.meticulousresearch.com/download-sample-report/?cp_id=3875